Viewing Study NCT01250951


Ignite Creation Date: 2025-12-24 @ 11:44 PM
Ignite Modification Date: 2026-04-25 @ 4:59 AM
Study NCT ID: NCT01250951
Status: COMPLETED
Last Update Posted: 2016-12-12
First Post: 2010-11-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndrome View
None Thalassemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Iron Overload View
None hemotranfusion View
None deferasirox View
None ferritin View
None Rare anemia View
None Transfusional Iron Overload View